Related Experiment Video
Updated: Apr 3, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
Amiodarone-Induced Life-Threatening Refractory Hypotension
Deepak Doshi1, Ravi Jayawardana2
1Director of Medical Service, Roma Hospital, Roma, QLD, Australia.
Intravenous amiodarone can cause severe hypotension in patients with atrial fibrillation. This case highlights a rare but serious adverse event requiring intensive medical intervention.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Amiodarone is a common emergency department treatment for arrhythmias.
- The incidence of amiodarone-related adverse events, especially life-threatening ones, is not well-documented.
- Existing literature offers limited information on severe adverse effects of amiodarone.
Observation:
- A male patient presented with chest discomfort and rapid atrial fibrillation.
- Initial beta-blocker treatment was ineffective for his paroxysmal atrial fibrillation.
- Amiodarone was administered as a second-line agent for rate control.
Findings:
- The patient developed severe, refractory hypotension following intravenous amiodarone administration.
- This hypotension necessitated inotropic support.
- Rapid-sequence intubation was required due to the severity of the adverse event.
Implications:
- Intravenous amiodarone carries a risk of causing severe and refractory hypotension.
- Clinicians should be vigilant for this potential adverse effect in emergency settings.
- This case underscores the importance of monitoring hemodynamic stability during amiodarone infusion.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Cardiopulmonary Resuscitation IV: Pharmacological Management
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

